Pelthos Therapeutics (PTHS) shares fell ~35% to $10.79 on Friday after the company agreed to merge with Castle Creek Biosciences (CCBS), expanding its portfolio into cell and gene therapies for serious skin diseases. Castle Creek shareholders will receive 5.2M To ensure th
Pelthos Therapeutics (PTHS) shares fell ~35% to $10.79 on Friday after the company agreed to merge with Castle Creek Biosciences (CCBS), expanding its portfolio into cell and gene therapies for serious skin diseases.
Castle Creek shareholders will receive 5.2M To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
